Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers

This study has been terminated.
(Low Recruitment)
Sponsor:
Collaborator:
Singapore Cancer Syndicate.
Information provided by:
Sidney Kimmel Comprehensive Cancer Center
ClinicalTrials.gov Identifier:
NCT00539318
First received: October 2, 2007
Last updated: August 13, 2009
Last verified: August 2009
  Purpose

The proposal seeks to establish:

  • A comprehensive compilation (database) of clinical information comprising clinical, histopathological, treatment and follow-up characteristics of past and future gastrointestinal cancer (GIC) cases in Singapore that can be shared by investigators. The characteristics will include clinical (eg age, sex, stage), histopathological (eg. grade, type), treatment (eg. treatment status, regimens) and outcome data (eg. survival, toxicity) from medical records.
  • A collection (bank) of corresponding frozen and fixed tissue, blood and processed samples (enriched blood mononuclear cells, protein, RNA, DNA, tissue arrays) in Singapore that can be shared by the investigators.
  • A gastrointestinal cancer co-operative group (GCCG) of clinicians and scientists researching prognostic and predictive markers in GIC, which will benefit from the multidisciplinary knowledge, information and samples of its members.

Condition Intervention
Gastrointestinal Cancer
Procedure: Blood drawing

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Infrastructure for Developing Gastrointestinal Cancer Prognostic and Predictive Markers

Resource links provided by NLM:


Further study details as provided by Sidney Kimmel Comprehensive Cancer Center:

Primary Outcome Measures:
  • there is no primary outcome measures in this study [ Time Frame: no time frame is provided ]

Estimated Enrollment: 60
Study Start Date: August 2007
Study Completion Date: July 2009
Groups/Cohorts Assigned Interventions
GI Cancer Procedure: Blood drawing
Once when enroll in study

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

GI cancer

Criteria

Inclusion Criteria:

  • Patients with cancers of the gastrointestinal tract (eg. colorectal, gastric, pancreatic, esophageal)
  • Lower age limit: 18; Upper age limit: None

GENDER CRITERIA: None

RACIAL CRITERIA: None

Exclusion Criteria:

  • none
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00539318

Locations
Singapore
Johns Hopkins Singapore International Medical Centre
Singapore, Singapore, 308433
Sponsors and Collaborators
Sidney Kimmel Comprehensive Cancer Center
Singapore Cancer Syndicate.
Investigators
Principal Investigator: Dr Alex Chang, MD JHS IMC
  More Information

No publications provided

Responsible Party: Alex Chang, Johns Hopkins Singapore International medical centre
ClinicalTrials.gov Identifier: NCT00539318     History of Changes
Other Study ID Numbers: JS0733, NA_00009934
Study First Received: October 2, 2007
Last Updated: August 13, 2009
Health Authority: Singapore: Domain Specific Review Boards

Additional relevant MeSH terms:
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases

ClinicalTrials.gov processed this record on July 31, 2014